Apr 1, 2025 · CEPI’s MERS programme seeks to advance candidate vaccines through Phase 2 trials and develop an investigational ready reserve that could be used to control future regional outbreaks.

$2.6m investment from CEPI to advance Uvax Bio’s MERS vaccine candidate into preclinical trials. Nanoparticle design mimics size and shape of MERS virus to trigger enhanced immune response. …

National Institute of Allergy and Infectious Diseases (NIAD). Walter Reed Army Institute of Research (WRAIR); Vanderbilt University.

Dec 21, 2023 · The project will see CEPI, Barinthus Bio, and the University of Oxford together take a MERS vaccine from early development through Phase II clinical trials.

Nov 14, 2025 · This Phase 2a, randomized, blinded, placebo-controlled, multi-center trial (MERS-201; NCT04588428) evaluated the safety, tolerability, and immunogenicity of INO-4700, a DNA vaccine …

Mar 25, 2025 · In a significant leap forward for combating the deadly Middle East Respiratory Syndrome (MERS) coronavirus, the Coalition for Epidemic Preparedness Innovations (CEPI) has announced a …

Nov 13, 2025 · The MERS-CoV spike (S) protein is the viral fusogen and the target of neutralizing antibodies, and has therefore been the focus of vaccine design efforts. Currently there are no …

Sep 18, 2023 · This is the third Phase I clinical trial of the ChAdOx1 MERS vaccine, developed by researchers at the University of Oxford’s Pandemic Sciences Institute. It is the first trial in older people.

Currently there is no vaccine or antiretroviral treatment for MERS-CoV infection. With support from Samsung, IVI will lead an international collaboration to advance the development of MERS vaccines …

Nov 21, 2025 · Vaccine candidates profiled in the Landscape are intended to provide greater durability and immunologic protection compared with existing strain-specific vaccines, target emerging variants …